Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1980 May;17(5):770–775. doi: 10.1128/aac.17.5.770

Effects of ribavirin on respiratory syncytial virus in vitro.

J F Hruska, J M Bernstein, R G Douglas Jr, C B Hall
PMCID: PMC283873  PMID: 7396465

Abstract

Ribavirin was demonstrated to have an antiviral effect on respiratory syncytial virus in vitro. A 50% reduction in plaque number was observed at concentrations of 3 or 10 micrograms of ribavirin per ml. This effect was observed when the drug was added as late as 12 h postinfection. At concentrations of greater than 10 micrograms of ribavirin per ml, the size of the syncytial plaque also noticeably decreased. Ribavirin similarly decreased the number of infectious units released into the culture supernatant. The antiviral effect was observed to be inversely related to the size of the viral inoculum, although all concentrations above 3.2 micrograms of ribavirin per ml visibly lessened the cytopathic effect regardless of the inoculum. Cloning of respiratory synctial virus in inhibitory concentrations of ribavirin failed to show increased resistance to the drug.

Full text

PDF
770

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cohen A., Togo Y., Khakoo R., Waldman R., Sigel M. Comparative clinical and laboratory evaluation of the prophylactic capacity of ribavirin, amantadine hydrochloride, and placebo in induced human influenza type A. J Infect Dis. 1976 Jun;133 (Suppl):A114–A120. doi: 10.1093/infdis/133.supplement_2.a114. [DOI] [PubMed] [Google Scholar]
  2. Durr F. E., Lindh H. F. Efficacy of ribavirin against influenza virus in tissue culture and in mice. Ann N Y Acad Sci. 1975 Aug 8;255:366–371. doi: 10.1111/j.1749-6632.1975.tb29244.x. [DOI] [PubMed] [Google Scholar]
  3. Durr F. E., Lindh H. F., Forbes M. Efficacy of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide against influenza virus infections in mice. Antimicrob Agents Chemother. 1975 May;7(5):582–586. doi: 10.1128/aac.7.5.582. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Huffman J. H., Sidwell R. W., Khare G. P., Witkowski J. T., Allen L. B., Robins R. K. In vitro effect of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) on deoxyribonucleic acid and ribonucleic acid viruses. Antimicrob Agents Chemother. 1973 Feb;3(2):235–241. doi: 10.1128/aac.3.2.235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Khare G. P., Sidwell R. W., Witkowski J. T., Simon L. N., Robins R. K. Suppression by 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) of influenza virus-induced infections in mice. Antimicrob Agents Chemother. 1973 Apr;3(4):517–522. doi: 10.1128/aac.3.4.517. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Kim H. W., Canchola J. G., Brandt C. D., Pyles G., Chanock R. M., Jensen K., Parrott R. H. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969 Apr;89(4):422–434. doi: 10.1093/oxfordjournals.aje.a120955. [DOI] [PubMed] [Google Scholar]
  7. Magnussen C. R., Douglas R. G., Jr, Betts R. F., Roth F. K., Meagher M. P. Double-blind evaluation of oral ribavirin (Virazole) in experimental influenza A virus infection in volunteers. Antimicrob Agents Chemother. 1977 Oct;12(4):498–502. doi: 10.1128/aac.12.4.498. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Oxford J. S. Effects of 1-beta-D-ribofuranosyl 1, 2, 4-triazole-3-carboxamide on influenza virus replication and polypeptide synthesis. J Antimicrob Chemother. 1975 Dec;1(4 Suppl):71–76. doi: 10.1093/jac/1.suppl_4.71. [DOI] [PubMed] [Google Scholar]
  9. Parrott R. H., Kim H. W., Brandt C. D., Chanock R. M. Potential of attenuated respiratory syncytial virus vaccine for infants and children. Dev Biol Stand. 1975;28:389–399. [PubMed] [Google Scholar]
  10. Prince G. A., Jenson A. B., Horswood R. L., Camargo E., Chanock R. M. The pathogenesis of respiratory syncytial virus infection in cotton rats. Am J Pathol. 1978 Dec;93(3):771–791. [PMC free article] [PubMed] [Google Scholar]
  11. SOMMERVILLE R. G. RESPIRATORY SYNCYTIAL VIRUS IN ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS. Lancet. 1963 Dec 14;2(7320):1247–1248. doi: 10.1016/s0140-6736(63)90894-8. [DOI] [PubMed] [Google Scholar]
  12. Scholtissek C. Inhibition of influenza RNA synthesis by virazole (ribavirin). Arch Virol. 1976;50(4):349–352. doi: 10.1007/BF01317961. [DOI] [PubMed] [Google Scholar]
  13. Sidwell R. W., Huffman J. H., Khare G. P., Allen L. B., Witkowski J. T., Robins R. K. Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science. 1972 Aug 25;177(4050):705–706. doi: 10.1126/science.177.4050.705. [DOI] [PubMed] [Google Scholar]
  14. Stephen E. L., Dominik J. W., Moe J. B., Walker J. S. Therapeutic effects of ribavirin given by the intraperitoneal or aerosol route against influenza virus infections in mice. Antimicrob Agents Chemother. 1976 Sep;10(3):549–554. doi: 10.1128/aac.10.3.549. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Suganuma T., Ishida N. An evaluation of a new antiviral agent "virazole" against influenza virus infections. Tohoku J Exp Med. 1973 Aug;110(4):405–406. doi: 10.1620/tjem.110.405. [DOI] [PubMed] [Google Scholar]
  16. Togo Y., McCracken E. A. Double-blind clinical assessment of ribavirin (virazole) in the prevention of induced infection with type B influenza virus. J Infect Dis. 1976 Jun;133 (Suppl):A109–A113. doi: 10.1093/infdis/133.supplement_2.a109. [DOI] [PubMed] [Google Scholar]
  17. Witkowski J. T., Robins R. K., Sidwell R. W., Simon L. N. Design, synthesis, and broad spectrum antiviral activity of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides. J Med Chem. 1972 Nov;15(11):1150–1154. doi: 10.1021/jm00281a014. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES